Harvard Bioscience (HBIO) Accumulated Expenses (2010 - 2026)

Harvard Bioscience (HBIO) has 17 years of Accumulated Expenses data on file, last reported at $2.2 million in Q1 2026.

• Accumulated Expenses for Q1 2026 came in at $2.2 million, up 573.37% year-over-year; the trailing twelve-month figure through Mar 2026 was $2.2 million (up 573.37% YoY), and the FY2025 annual result was $1.8 million, up 5.89% from the prior year.
• Accumulated Expenses advanced to $2.2 million in Q1 2026 per HBIO's latest filing, from $1.8 million in the prior quarter.
• Over five years, Accumulated Expenses peaked at $3.9 million in Q4 2023 and troughed at $242000.0 in Q1 2022.
• A 5-year average of $1.8 million and a median of $1.8 million in 2025 frame the typical range for Accumulated Expenses.
• The sharpest annual moves came in 2022 and 2023: Accumulated Expenses plunged 91.07% in 2022, then jumped 1366.04% in 2023.
• A 5-year view of Accumulated Expenses shows it stood at $268000.0 in 2022, then jumped by 1366.04% to $3.9 million in 2023, then sank by 56.38% to $1.7 million in 2024, then gained by 5.89% to $1.8 million in 2025, then climbed by 19.83% to $2.2 million in 2026.
• Business Quant data shows HBIO's Accumulated Expenses at $2.2 million in Q1 2026, $1.8 million in Q4 2025, and $304000.0 in Q3 2025.